All the latest data and announcements from the Australian Stock Exchange
Adopting an intelligent and agile approach to clinical research and development, our experienced team are passionate in our commitment to the quality of our programmes.
Paradigm reports on Phase 2b OA/BMEL Clinical Trial (18 December 2018)
Paradigm Biopharmaceuticals Ltd is pleased to announce that it has met its primary endpoint of its phase 2b randomised double-blind placebo-controlled multi-centre clinical trial.
Please see our ASX announcements and the video below for more information.
A key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.